[Chronic myeloid leukemia: from cytogenetics to molecular biology].
Chronic myeloid leukaemia (CML) is an excellent model for the study of molecular rearrangements caused by a cytogenetic anomaly associated with a disease. The formation of a Philadelphia chromosome by translocation between chromosomes 9 and 22 provokes the breaking and migration of a cellular oncogen (ABL), located in the 9q34 region, towards chromosome 22 and the 22q11 region where the PHL gene is situated. This gene is broken in the bcr area the rearrangements of which are specific to CML. The ABL and PHL genes fragments fuse together, creating a new hybrid gene which is transcribed into an 8.5 kilobase messenger RNA specific to CML. This RNA is translated into a 210 kilodalton protein whose abnormally high tyrosine kinase activity seems to contribute to the development of the disease. Genetic engineering techniques improve our understanding of CML molecular mechanisms and can be very useful to clinicians as they permit the diagnosis of CML in some cases devoid of chromosomal markers, and the detection of a possible relapse in marrow-grafted patients with a much greater sensitivity (one in 100,000 cells) than that of cytogenetics.
Aissaoui
Z
Z
Interne des Hôpitaux, stagiaire à l'unité 124 INSERM, Institut de Recherches sur le Cancer de Lille.
Lai
J
J
Fenaux
P
P
Kerckaert
J P
JP
D003582:Cytogenetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D008967:Molecular Biology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics; D014178:Translocation, Genetic / Q000235:genetics
Leucémie myéloïde chronique: de la cytogénétique à la biologie moléculaire.